Post-Traumatic Stress Disorder – Unmet Need – Detailed, Expanded Analysis: Moderate to Severe PTSD (US/EU)

Although multiple guidelines recommend treating post-traumatic stress disorder (PTSD) with psychotherapy first, such an approach does not suffice for many patients, necessitating the use of pharmacological agents. The need for drug treatment is especially true for moderate and severe cases. Pharmacologic options for PTSD are limited; only two agents are FDA-approved, and others are used off-label. Lykos Therapeutics’ MDMA-assisted psychotherapy has been submitted for FDA approval, and Otsuka and Lundbeck reported positive Phase 2 and 3 results for Rexulti in combination with sertraline, suggesting that there may be new options for PTSD management. Our content examines the key drivers of clinical decision-making in moderate to severe PTSD and prescriber perceptions of available treatments, enabling the identification of opportunities within the moderate to severe PTSD therapy market.

Questions answered

  • Which clinical / nonclinical attributes drive psychiatrists’ decision-making in the treatment of moderate to severe PTSD, which have limited impact, and which are hidden opportunities?
  • How do psychiatrists rate the performance of key current therapies on treatment drivers and goals for moderate to severe PTSD?
  • What is the relative level of need for improved treatment options in multiple psychiatry indications, including moderate to severe PTSD?
  • Based on a conjoint analysis and TPP simulation, what trade-offs between efficacy, safety, convenience of administration, and price are psychiatrists willing to make for a hypothetical new therapy to treat moderate to severe PTSD?

Product description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Key feature:

The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European psychiatrists fielded in January 2024

Key companies: Otsuka Pharmaceutical, Lundbeck, Viatris, Apotex

Key drugs: Rexulti, sertraline, paroxetine, venlafaxine, aripiprazole, prazosin

launch Related Market Assessment Reports